These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 11885732)

  • 1. Meningococcal disease and vaccination in North America.
    Pollard AJ; Scheifele D
    J Paediatr Child Health; 2001 Oct; 37(5):S20-7. PubMed ID: 11885732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model.
    Vickers DM; Anonychuk AM; De Wals P; Demarteau N; Bauch CT
    Vaccine; 2015 Jan; 33(1):268-75. PubMed ID: 24103896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The changing epidemiology of meningococcal disease in North America 1945-2010.
    Baccarini C; Ternouth A; Wieffer H; Vyse A
    Hum Vaccin Immunother; 2013 Jan; 9(1):162-71. PubMed ID: 23108355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec.
    De Wals P; De Serres G; Niyonsenga T
    JAMA; 2001 Jan; 285(2):177-81. PubMed ID: 11176810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000-2013: Vaccine program impact assessment.
    Wormsbecker AE; Wong K; Jamieson FB; Crowcroft NS; Deeks SL
    Vaccine; 2015 Oct; 33(42):5678-5683. PubMed ID: 26299749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving meningococcal immunization strategies.
    Sáfadi MA; Bettinger JA; Maturana GM; Enwere G; Borrow R;
    Expert Rev Vaccines; 2015 Apr; 14(4):505-17. PubMed ID: 25494168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Epidemiology and Trends in Meningococcal Disease-United States, 1996-2015.
    MacNeil JR; Blain AE; Wang X; Cohn AC
    Clin Infect Dis; 2018 Apr; 66(8):1276-1281. PubMed ID: 29126310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in the Population Structure of Invasive Neisseria meningitidis in the United States After Quadrivalent Meningococcal Conjugate Vaccine Licensure.
    Wang X; Shutt KA; Vuong JT; Cohn A; MacNeil J; Schmink S; Plikaytis B; Messonnier NE; Harrison LH; Clark TA; Mayer LW
    J Infect Dis; 2015 Jun; 211(12):1887-94. PubMed ID: 25556253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiological and Molecular Characterization of Invasive Meningococcal Disease in Italy, 2008/09-2012/13.
    Neri A; Pezzotti P; Fazio C; Vacca P; D'Ancona FP; Caporali MG; Stefanelli P
    PLoS One; 2015; 10(10):e0139376. PubMed ID: 26445461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines.
    Villena R; Safadi MAP; Valenzuela MT; Torres JP; Finn A; O'Ryan M
    Hum Vaccin Immunother; 2018 May; 14(5):1042-1057. PubMed ID: 29667483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospects for vaccine prevention of meningococcal infection.
    Harrison LH
    Clin Microbiol Rev; 2006 Jan; 19(1):142-64. PubMed ID: 16418528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Invasive meningococcal disease in the Czech Republic - analysis of the epidemiological situation and vaccination strategy recommendations].
    Křížová P; Vacková Z; Musílek M; Kozáková J
    Epidemiol Mikrobiol Imunol; 2013 Dec; 62(4):138-47. PubMed ID: 24467175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States.
    Lingappa JR; Rosenstein N; Zell ER; Shutt KA; Schuchat A; Perkins BA;
    Vaccine; 2001 Aug; 19(31):4566-75. PubMed ID: 11483285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meningococcal vaccine evolution.
    Bona G; Guidi C
    J Prev Med Hyg; 2012 Sep; 53(3):131-5. PubMed ID: 23362617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991-2000.
    Baker MG; Martin DR; Kieft CE; Lennon D
    J Paediatr Child Health; 2001 Oct; 37(5):S13-9. PubMed ID: 11885731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada.
    Bettinger JA; Scheifele DW; Le Saux N; Halperin SA; Vaudry W; Tsang R;
    Pediatr Infect Dis J; 2009 Mar; 28(3):220-4. PubMed ID: 19209096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of an Immunization Campaign to Control an Increased Incidence of Serogroup B Meningococcal Disease in One Region of Quebec, Canada.
    De Wals P; Deceuninck G; Lefebvre B; Tsang R; Law D; De Serres G; Gilca V; Gilca R; Boulianne N
    Clin Infect Dis; 2017 May; 64(9):1263-1267. PubMed ID: 28207068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of meningococcal infections in the first 2 years of life.
    Woods CR
    Pediatr Ann; 2013 Aug; 42(8):164-71. PubMed ID: 23910030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines.
    Pace D; Pollard AJ
    Arch Dis Child; 2007 Oct; 92(10):909-15. PubMed ID: 17895339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology of invasive meningococcal disease in Cyprus 2004 to 2018.
    Koliou M; Kasapi D; Mazeri S; Maikanti P; Demetriou A; Skordi C; Agathocleous M; Tzanakaki G; Constantinou E
    Euro Surveill; 2020 Jul; 25(30):. PubMed ID: 32734853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.